Compare EXPO & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | ALKS |
|---|---|---|
| Founded | 1967 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.7B |
| IPO Year | 1990 | 1991 |
| Metric | EXPO | ALKS |
|---|---|---|
| Price | $72.33 | $28.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $81.00 | $42.85 |
| AVG Volume (30 Days) | 473.8K | ★ 1.9M |
| Earning Date | 02-05-2026 | 10-28-2025 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | ★ 2.03 | 2.02 |
| Revenue | $531,142,000.00 | ★ $1,521,338,000.00 |
| Revenue This Year | $5.31 | N/A |
| Revenue Next Year | $7.93 | $24.22 |
| P/E Ratio | $35.48 | ★ $14.10 |
| Revenue Growth | ★ 4.43 | 1.08 |
| 52 Week Low | $63.81 | $25.17 |
| 52 Week High | $97.57 | $36.45 |
| Indicator | EXPO | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 46.34 |
| Support Level | $70.32 | $27.69 |
| Resistance Level | $75.01 | $28.53 |
| Average True Range (ATR) | 1.75 | 0.85 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 32.28 | 42.22 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.